Page last updated: 2024-12-07

safinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

safinamide: short-acting inhibitor of MOA-B; FCE 26743 is (S)-isomer, FCE 28073 is (R)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131682
CHEMBL ID396778
CHEMBL ID48582
CHEBI ID134718
SCHEMBL ID69350
MeSH IDM0403007

Synonyms (72)

Synonym
bdbm50078694
(s)-2-[4-(3-fluoro-benzyloxy)-benzylamino]-propionamide; compound with methanesulfonic acid
(+-)-(s)-2-((p-((m-fluorobenzyl)oxy)benzyl)amino)propionamide
n2-(4-((3-fluorbenzyl)oxy)benzyl)-l-alaninamid
90enl74sig ,
safinamide [usan:inn]
ec 603-772-2
2-(4-(3-fluorobenzyloxy)benzylamino)propionamide
(s)-2-(((4-((3-fluorophenyl)methoxy)phenyl)methyl)amino)propanamide
xadago
propanamide, 2-(((4-((3-fluorophenyl)methoxy)phenyl)methyl)amino)-, (s)-
unii-90enl74sig
HY-70057
fce-26743
emd-1195686
safinamide
chembl396778 ,
(2s)-2-[({4-[(3-fluorophenyl)methoxy]phenyl}methyl)amino]propanamide
bdbm19187
CHEBI:134718
emd 1195686
CHEMBL48582 ,
133865-89-1
(2s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
D10158
safinamide (usan/inn)
(s)-2-((4-((3-fluorobenzyl)oxy)benzyl)amino)propanamide
AKOS016002015
CS-0556
NCGC00346529-01
S5357
2(s)-(4-(3-fluorobenzyloxy)benzylamino)propionamide
safinamide [usan]
safinamide [who-dd]
safinamide [inn]
safinamide [mi]
(s)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide
(s)-2[4-(3-fluorobenzyloxy)benzylamino] propanamide
(s)-2[4-(3-fluorobenzyloxy)benzylamino]propanamide
(5)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide
NEMGRZFTLSKBAP-LBPRGKRZSA-N
SCHEMBL69350
(s)-2-((4-(3-fluorobenzoxy)benzyl)amino)propanamide
gtpl8291
AC-26829
S0935
(s)-2-[[4-[(3-fluorobenzyl)oxy]benzyl]amino]propionamide
(s)-2-[[4-[(3-fluorobenzyl)oxy]benzyl]amino]propanamide
J-506604
(s)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide methansulfonate
EX-A2759
DB06654
A888007
mfcd00897036
Q2211523
emd 1195686;fce 26743;emd-1195686;emd1195686;fce-26743
BCP12082
HMS3886M21
AMY38831
ER-0076
CCG-267489
NCGC00346529-03
2(s)-[4-(3-fluorobenzyloxy) benzylamino] propionamide
(2s)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide
safinamide mesylate intermediate 2
DTXSID601010282 ,
safinamide:(s)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamidemethansulfonate
EN300-18567503
safinamida
safinamidum
dtxcid701436700
n04bd03

Research Excerpts

Overview

Safinamide is a novel molecule in relation to addressing NMS due to its multifocal mechanism of action with both dopaminergic and non-dopaminergic properties. Safinamide seems to be an effective adjunctive treatment in PD patients treated with bilateral STN-DBS.

ExcerptReferenceRelevance
"Safinamide is a novel molecule in relation to addressing NMS due to its multifocal mechanism of action with both dopaminergic and non-dopaminergic properties."( Effects of safinamide on pain in patients with fluctuating Parkinson's disease.
Falkenburger, B; Grigoriou, S; Hausbrand, D; Leta, V; Martínez-Martín, P; Odin, P; Ray Chaudhuri, K; Reichmann, H; Rukavina, K, 2021
)
1.73
"Safinamide is a highly selective and reversible monoamine oxidase B inhibitor introduced in the European Union, Japan, and the United States as an adjunctive agent to levodopa in PD patients with motor fluctuation. "( Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
Fujioka, S; Kurihara, K; Mishima, T; Tsuboi, Y, 2022
)
2.44
"Safinamide is a new add-on drug to levodopa for the treatment of Parkinson's disease (PD) with motor fluctuations. "( Spanish expert consensus on the use of safinamide in Parkinson's disease.
Arbelo, JM; Blázquez Estrada, M; Calopa Garriga, M; Campos-Arillo, VM; Garcia Ruiz, PJ; Gómez Esteban, JC; Grandas, F; Leiva Santana, C; Martínez Castrillo, JC; Mir, P; Salvador Aliaga, A; Valldeoriola, F; Vivancos Matellano, F; Yáñez Baña, RM,
)
1.84
"Safinamide seems to be an effective adjunctive treatment in PD patients treated with bilateral STN-DBS, leading to an improvement of motor complications, mood and pain."( Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.
Artusi, CA; Balestrino, R; Bonvegna, S; Fabbri, M; Imbalzano, G; Lopiano, L; Mancini, F; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M, 2022
)
2.54
"Safinamide is a recent multimodal antiparkinsonian drug that inhibits monoamine oxidase B and modulates the glutamatergic system with positive effects on motor and nonmotor symptoms of Parkinson's disease (PD). "( Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.
Bergmans, B; Bourgeois, P; Cras, P; De Klippel, N; Dethy, S; Franco, G; Garraux, G; Geens, K; Jacquerye, P; Jeanjean, A; Krygier, C; Supiot, F; Van der Linden, C, 2023
)
2.65
"Safinamide is a multimodal drug with proven efficacy as an adjunct to levodopa."( The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
Cattaneo, C; Chen, S; Dong, X; Liu, C; Lu, Z; Pan, X; Shang, H; Sun, X; Tan, Y; Tao, E; Tian, Y; Wang, B; Wei, Q; Xu, P, 2022
)
1.66
"Safinamide is a monoamine oxidase B (MAOB) inhibitor that facilitates CDS."( The effects of safinamide on dysphagia in Parkinson's disease.
Hirano, M; Isono, C; Nagai, Y; Samukawa, M, 2023
)
1.98
"Safinamide is a unique treatment modulating both dopaminergic and glutamatergic systems."( Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
Bonizzoni, E; Cattaneo, C; Jost, WH, 2020
)
1.59
"Safinamide is a reversible and selective monoamine oxidase-B (MAO-B) and sodium channel inhibitor with demonstrated efficacy in mid-to late-stage Parkinson's disease (PD) as an adjunct to l-DOPA. "( Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
Hattori, N; Nomoto, M; Sasagawa, Y; Tsuboi, Y; Yamamoto, A, 2020
)
2.31
"Safinamide is a novel, selective, and reversible inhibitor of monoamine oxidase B expected to increase dopamine levels in the brain and improve the symptoms of Parkinson's disease."( [Safinamide Mesilate (Equfina
Ishida, T; Koebisu, M, 2020
)
2.19
"Safinamide is a newly approved add-on drug to treat Parkinson's disease, and previously studies suggest safinamide could have a potential role on neuroprotection."( The Protective Effect of Safinamide in Ischemic Stroke Mice and a Brain Endothelial Cell Line.
Kong, S; Sun, R; Wei, G; Xu, T, 2020
)
1.58
"Safinamide (SF) is a third-generation monoamine-oxidase-B inhibitor that proved efficacy as add-on to levodopa in fluctuating Parkinson's disease (PD) patients. "( The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study.
Alborghetti, M; Bianchini, E; Galli, S; Giovannelli, M; Pontieri, FE; Rinaldi, D; Salvetti, M; Sforza, M, 2021
)
2.33
"Safinamide is a novel inhibitor of monoamine oxidase B (MAOB) with neuroprotective properties."( Neuroprotective and neuro-survival properties of safinamide against methamphetamine-induced neurodegeneration: Hypothetic possible role of BDNF/TrkB/PGC-1α signaling pathway and mitochondrial uncoupling protein -2(UCP-2).
Heidarian, S; Motaghinejad, M; Safari, S; Sepehr, A; Taheri, F, 2020
)
1.53
"Safinamide is a monoamine-oxidase-B inhibitor with peculiar features. "( Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study.
Assogna, F; Caltagirone, C; Pontieri, FE; Rinaldi, D; Salvetti, M; Savini, C; Sforza, M; Spalletta, G, 2021
)
3.51
"Safinamide is a new monoamine oxidase B inhibitor, also exerting a non-dopaminergic effect, recently approved as add-on therapy in fluctuating PD patients."( Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study.
De Mase, A; De Micco, R; Giordano, A; Satolli, S; Siciliano, M; Tedeschi, G; Tessitore, A, 2022
)
1.83
"Safinamide is a drug with an innovative mechanism of action, dopaminergic and non-dopaminergic, that includes the reversible inhibition of the monoamine oxidase-B (MAO-B) enzyme and the modulation of excessive glutamate release through the use- and state-dependent blockade of the sodium channels."( Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.
Bonizzoni, E; Cattaneo, C; Keywood, C; Kottakis, I; Lazzeri, G; Müller, T, 2017
)
1.5
"Safinamide is an important adjunct to standard parkinsonian medication for alleviating pain in PD."( Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Akhter, S; Malik, SH; Qureshi, AR; Rana, AQ; Rana, R; Rizvi, SFH; Sarfraz, Z; Vannabouathong, C, 2018
)
1.2
"Safinamide (Xadago) is a novel dual-mechanism drug that has been approved in the European Union and United States as add-on treatment to levodopa in Parkinson's disease therapy. "( Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S, 2018
)
3.37
"Safinamide is a compound under investigation for use in the treatment of Parkinson's disease for combination with pharmacological therapy currently available. "( Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
Di Paolo, T; Grégoire, L; Jourdain, VA; Roach, A; Townsend, M, 2013
)
3.28
"Safinamide is an α-aminoamide derivative with a combined, dopaminergic and non-dopaminergic mode of action."( Safinamide for the treatment of Parkinson's disease.
Dézsi, L; Vécsei, L, 2014
)
2.57
"Safinamide (NW-1015) is a novel drug with multiple actions."( Safinamide for the treatment of Parkinson's disease.
Borgohain, R; Jabeen, SA; Kandadai, RM; Kanikannan, MA, 2014
)
2.57
"Safinamide (Xadago(®)) is an oral α-aminoamide derivative developed by Newron for the treatment of Parkinson's disease (PD). "( Safinamide: first global approval.
Deeks, ED, 2015
)
3.3
"Safinamide is a novel α-aminoamide with dopaminergic and non-dopaminergic properties developed as adjunctive therapy for patients with PD. "( Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
Bonizzoni, E; Cattaneo, C; Ferla, RL; Sardina, M, 2015
)
2.18
"Safinamide (Xadago™) is an oral α-aminoamide derivative marketed for the treatment of Parkinson's disease (PD). "( Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
Abreu, D; Fabbri, M; Ferreira, JJ; Rosa, MM, 2015
)
2.14
"Safinamide is a novel instrument for the drug therapy of Parkinson's disease with better safety and tolerability particularly concerning diarrhea than inhibitors of catechol-O-methyltransferase, like entacapone, according to an indirect comparison within a meta-analysis with entacapone."( Safinamide for symptoms of Parkinson's disease.
Müller, T, 2015
)
2.58
"Safinamide (SAF) is a new drug developed for the treatment of Parkinson's disease (PD). "( Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
Stocchi, F; Torti, M, 2016
)
2.11
"Safinamide is an investigational drug for PD currently in development as add-on therapy to both dopamine agonists and levodopa."( An expert opinion on safinamide in Parkinson's disease.
Bonanni, L; Onofrj, M; Thomas, A, 2008
)
1.39
"Safinamide is a promising investigational drug for PD with a novel mode of action. "( An expert opinion on safinamide in Parkinson's disease.
Bonanni, L; Onofrj, M; Thomas, A, 2008
)
2.11
"Safinamide is an α-aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add-on to dopamine agonist (DA) therapy in early-stage PD. "( A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients.
Anand, R; Bhatt, M; Borgohain, R; Giuliani, R; Lucini, V; Onofrj, M; Schapira, AH; Stocchi, F, 2012
)
2.07
"Safinamide is an α-aminoamide with both dopaminergic and non-dopaminergic mechanisms of action in Phase III clinical development as a once-daily add-on to dopamine agonist (DA) therapy for early Parkinson's disease (PD)."( Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
Anand, R; Bhatt, M; Borgohain, R; Giuliani, R; Lorenzana, P; Lucini, V; Onofrj, M; Schapira, AH; Stocchi, F, 2013
)
2.11
"Safinamide is an α-aminoamide derivative that is currently in Phase III clinical trial development as an add-on therapy to levodopa or dopamine agonists for patients with Parkinson's disease. "( Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor.
Collins-Praino, LE; Lobianco, C; Podurgiel, S; Randall, PA; Roach, A; Salamone, JD; Yohn, S, 2013
)
2.14
"Safinamide is a novel neuroprotectant combining sodium and calcium channel blocking properties with selective, reversible monoamine oxidase type B (MAO B) inhibition. "( Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition.
Caccia, C; Cattaneo, C; Fariello, RG; Maj, R; Marzo, A,
)
1.81

Effects

Safinamide has a multimodal mechanism of action, dopaminergic (reversible MAO-B inhibition) and non-dopaminergic. Safinamide might be beneficial for both motor andnon-motor symptoms.

Savinamide has been approved in over 20 countries globally for fluctuating PD as add-on therapy to levodopa regimens. Safinamide has neuroprotective and neurorescuing effects in MPTP-treated mice, in rat kainic acid, and in the gerbil ischemia model.

ExcerptReferenceRelevance
"Safinamide has a multimodal mechanism of action, dopaminergic (reversible MAO-B inhibition) and non-dopaminergic (modulation of the abnormal glutamate release), that might be beneficial for both motor and non-motor symptoms."( Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.
Castellani, P; Cattaneo, C; Kulisevsky, J; Tubazio, V, 2018
)
1.52
"Safinamide has a unique pharmacological profile, which combines modulation of dopamine metabolism by reversible, highly specific monoamine oxidase-B inhibition, blockage of voltage-dependent sodium channels, modulation of calcium channels and of glutamate release induced by abnormal neuronal activity."( Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
Müller, T, 2013
)
1.45
"Safinamide has been shown to be effective and safe in improving motor fluctuations, motor symptoms and the subjective perception of disease severity in PD patients previously receiving rasagiline and in those receiving low-dose safinamide, all of which is accompanied by a good safety profile."( Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.
Diezma-Martín, A; García-Meléndez, DD; López-Ariztegui, N; Morales-Casado, MI, 2023
)
2.65
"Safinamide has been approved in over 20 countries globally for fluctuating PD as add-on therapy to levodopa regimens for the management of 'off' episodes."( The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature.
Caccia, C; Jost, WH; Pagonabarraga, J; Tinazzi, M, 2021
)
1.34
"Safinamide has been recently approved as an add-on to levodopa therapy for Parkinson disease. "( Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.
Brugnoli, A; Caccia, C; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sardina, M; Vailati, S, 2018
)
3.37
"Safinamide has a multimodal mechanism of action, dopaminergic (reversible MAO-B inhibition) and non-dopaminergic (modulation of the abnormal glutamate release), that might be beneficial for both motor and non-motor symptoms."( Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.
Castellani, P; Cattaneo, C; Kulisevsky, J; Tubazio, V, 2018
)
1.52
"Safinamide has a unique pharmacological profile, which combines modulation of dopamine metabolism by reversible, highly specific monoamine oxidase-B inhibition, blockage of voltage-dependent sodium channels, modulation of calcium channels and of glutamate release induced by abnormal neuronal activity."( Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
Müller, T, 2013
)
1.45
"Safinamide has also undergone phase II investigation in PD patients with drug-induced dyskinesia (France, Germany, Austria, Canada and South Africa) or cognitive impairment (USA and Spain)."( Safinamide: first global approval.
Deeks, ED, 2015
)
2.58
"Safinamide has neuroprotective and neurorescuing effects in MPTP-treated mice, in the rat kainic acid, and in the gerbil ischemia model."( Safinamide: from molecular targets to a new anti-Parkinson drug.
Caccia, C; Calabresi, M; Curatolo, L; Faravelli, L; Fariello, RG; Maestroni, S; Maj, R; Salvati, P, 2006
)
2.5

Treatment

Safinamide is a unique treatment modulating both dopaminergic and glutamatergic systems. Safinamide pre-treatment (3, 10, 20 and 30 mg/kg) dose-dependently reduced LID scores.

ExcerptReferenceRelevance
"Safinamide is a unique treatment modulating both dopaminergic and glutamatergic systems."( Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
Bonizzoni, E; Cattaneo, C; Jost, WH, 2020
)
1.59
"Safinamide pre-treatment (3, 10, 20 and 30 mg/kg) dose-dependently reduced LID scores, in two acute and one semi-chronic experiment. "( Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
Di Paolo, T; Grégoire, L; Jourdain, VA; Roach, A; Townsend, M, 2013
)
3.28
"Treatment with safinamide was associated with significant increases of the total FAB score, SWCT-interference time score and UPDRS-III score."( Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study.
Assogna, F; Caltagirone, C; Pontieri, FE; Rinaldi, D; Salvetti, M; Savini, C; Sforza, M; Spalletta, G, 2021
)
2.4

Toxicity

Safinamide has been shown to be effective and safe in improving motor fluctuations, motor symptoms and the subjective perception of disease severity in PD patients.

ExcerptReferenceRelevance
" Adverse events caused the premature study discontinuation of 12 individuals (4."( Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Anand, R; Fox, SH; Hauser, RA; Jankovic, J; Jost, WH; Kenney, C; Kulisevsky, J; Pahwa, R; Poewe, W; Schapira, AH, 2017
)
0.73
" The most frequently reported adverse event was dyskinesia (in 40 [14."( Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Anand, R; Fox, SH; Hauser, RA; Jankovic, J; Jost, WH; Kenney, C; Kulisevsky, J; Pahwa, R; Poewe, W; Schapira, AH, 2017
)
0.73
" In total, 300 adverse events were classified as related to safinamide in 132 patients (44."( [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Bosse, D; Delf, M; Jost, WH; Kupsch, A; Mengs, J, 2018
)
1.01
" Adverse events occurred in 58."( Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
Hattori, N; Nomoto, M; Sasagawa, Y; Tsuboi, Y; Yamamoto, A, 2020
)
0.87
" Adverse events (AEs) occurred in 78."( Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study.
Hattori, N; Nomoto, M; Sasagawa, Y; Tsuboi, Y; Yamamoto, A, 2020
)
0.84
" Adverse events occurred in 30% of patients and led to drug discontinuation in 11% of cases."( The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study.
Alborghetti, M; Bianchini, E; Galli, S; Giovannelli, M; Pontieri, FE; Rinaldi, D; Salvetti, M; Sforza, M, 2021
)
0.89
"The results of the present study confirm that the overnight switch from rasagiline to safinamide is safe and well tolerated by patients."( Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study.
Caminiti, G; Casali, M; D'Antoni, V; Grassini, P; Stocchi, F; Tomino, C; Torti, M; Vacca, L; Volterrani, M, 2021
)
1.12
"To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions."( A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial.
Abbruzzese, G; Bergmans, B; Gomez-Esteban, JC; Jost, WH; Kägi, G; Kulisevsky, J; Raw, J; Stefani, A; Warnecke, T, 2021
)
1.08
"8% patients experienced adverse events, 27."( A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial.
Abbruzzese, G; Bergmans, B; Gomez-Esteban, JC; Jost, WH; Kägi, G; Kulisevsky, J; Raw, J; Stefani, A; Warnecke, T, 2021
)
0.85
"Safinamide was well tolerated as a treatment for PD, and there was no significant difference in the frequency and severity of adverse events between the safinamide and placebo groups."( Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
Fujioka, S; Kurihara, K; Mishima, T; Tsuboi, Y, 2022
)
2.44
" The adverse drug reactions were those already described in the patients' information leaflet."( Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.
Bergmans, B; Bourgeois, P; Cras, P; De Klippel, N; Dethy, S; Franco, G; Garraux, G; Geens, K; Jacquerye, P; Jeanjean, A; Krygier, C; Supiot, F; Van der Linden, C, 2023
)
1.2
" Safety was evaluated through the frequency of adverse events and serious adverse events, physical examination, vital signs, 12-lead electrocardiograms, and laboratory exams."( The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
Cattaneo, C; Chen, S; Dong, X; Liu, C; Lu, Z; Pan, X; Shang, H; Sun, X; Tan, Y; Tao, E; Tian, Y; Wang, B; Wei, Q; Xu, P, 2022
)
0.94
" There were no significant between-group differences for adverse events or serious adverse events."( The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
Cattaneo, C; Chen, S; Dong, X; Liu, C; Lu, Z; Pan, X; Shang, H; Sun, X; Tan, Y; Tao, E; Tian, Y; Wang, B; Wei, Q; Xu, P, 2022
)
0.94
" For safety outcomes, rasagiline was associated with a higher incidence of adverse events than placebo and safinamide."( Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R, 2023
)
1.12
" Unified Parkinson's Disease Rating Scale (UPDRS) total score and UPDRS part III score during on time were used to measure the overall severity of PD and motor complications, respectively, while the severity of adverse events was evaluated following the investigators' criteria."( SYNAPSES. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: post-hoc analysis of the Spanish study population.
Avilés, A; Esquivel, A; Freire-Álvarez, E; Gómez-Esteban, JC; Kulisevsky, J; Legarda-Ramírez, I; Mata-Álvarez-Santullano, M, 2023
)
1.13
" Increased safety concerns were undetected in any patient subgroup, although patients with cognitive impairment showed a slightly higher frequency of adverse events."( SYNAPSES. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: post-hoc analysis of the Spanish study population.
Avilés, A; Esquivel, A; Freire-Álvarez, E; Gómez-Esteban, JC; Kulisevsky, J; Legarda-Ramírez, I; Mata-Álvarez-Santullano, M, 2023
)
1.13
"This subanalysis further supports safinamide use as a safe and efficacious option for the management of motor fluctuations in different subgroups of levodopa-treated patients."( SYNAPSES. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: post-hoc analysis of the Spanish study population.
Avilés, A; Esquivel, A; Freire-Álvarez, E; Gómez-Esteban, JC; Kulisevsky, J; Legarda-Ramírez, I; Mata-Álvarez-Santullano, M, 2023
)
1.41
" The adverse events described were mild, with generalised weakness, dizziness, nausea, headache and alopecia."( Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.
Diezma-Martín, A; García-Meléndez, DD; López-Ariztegui, N; Morales-Casado, MI, 2023
)
1.2
"Safinamide has been shown to be effective and safe in improving motor fluctuations, motor symptoms and the subjective perception of disease severity in PD patients previously receiving rasagiline and in those receiving low-dose safinamide, all of which is accompanied by a good safety profile."( Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.
Diezma-Martín, A; García-Meléndez, DD; López-Ariztegui, N; Morales-Casado, MI, 2023
)
2.65
" MAO-B inhibitors may differ in adverse events (AEs)."( Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease using FDA adverse event reporting system.
Asano, H; Hatabu, A; Ikeda, K; Takagi, T; Tian, YS; Ueda, M, 2023
)
0.91
" Primary outcomes were the change from baseline in Unified Parkinson's Disease Rating Scale section III (UPDRS-III) and serious adverse events."( Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Abou-Setta, A; Aboulatta, L; Askin, N; Eltonsy, S; Haidar, L; Lavu, A; Peymani, P; Rabbani, R; Zarychanski, R, 2023
)
1.18
" The meta-analysis showed that both medications have a similar safety profile to placebo with regard to serious adverse events."( Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Abou-Setta, A; Aboulatta, L; Askin, N; Eltonsy, S; Haidar, L; Lavu, A; Peymani, P; Rabbani, R; Zarychanski, R, 2023
)
1.18

Pharmacokinetics

This randomized, parallel-group study evaluated the plasma pharmacokinetic profile of safinamide in 24 healthy Chinese men and women.

ExcerptReferenceRelevance
" In single dose trials blood sampling covered a 24 h-period in pharmacodynamic trials, 48 h-period in pharmacokinetic trials."( Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
Caccia, C; Cattaneo, C; Crivelli, F; Dal Bo, L; Fariello, RG; Ismaili, S; Marzo, A; Monti, NC, 2004
)
0.59
" Serial blood samples were collected over 240 h post dose to quantify safinamide parent drug and metabolite concentrations for pharmacokinetic evaluation."( Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects.
Fauchoux, N; Gallemann, D; Hermann, R; Johne, A; Krösser, S; Marquet, A; Wolna, P, 2012
)
0.85
"This randomized, parallel-group study evaluated the plasma pharmacokinetic profile of safinamide in 24 healthy Chinese men and women, randomly assigned to receive 50 or 100 mg of safinamide as a single dose, followed, after a 7-day washout, by multiple doses once daily for 7 days."( Pharmacokinetic and Safety Study of Single and Multiple Oral Doses of Safinamide in Healthy Chinese Volunteers.
Cattaneo, C; Jing, S; Leuratti, C; Vaja, V; Yuan, Y, 2023
)
1.37

Bioavailability

ExcerptReferenceRelevance
" Results from two phase I trials of the compound (single ascending dose and steady state at three doses), completed in March 2000, demonstrated that the drug is well tolerated with good bioavailability and linear pharmacokinetics [359652]."( Safinamide (Newron Pharmaceuticals).
Chazot, PL, 2001
)
1.75
"This paper describes three methods to bioassay safinamide (CAS 133865-89-1) in biological fluids of humans and laboratory animals for pharmacokinetic, toxicokinetic and bioavailability studies."( Bioassay of safinamide in biological fluids of humans and various animal species.
Dal Bo, L; Fibbioli, M; Marzo, A; Mazzucchelli, P, 2006
)
0.97
" The oral disintegrating tablet formulation of selegiline allows pregastric absorption, minimizing first-pass metabolism, thereby increasing selegiline bioavailability and reducing the concentration of amphetamine metabolites."( Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Chen, JJ; Fernandez, HH, 2007
)
0.34
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Safinamide may be used in PD to reduce l-dopa dosage and also represents a valuable therapeutic drug to test disease-modifying potential. Safinamide will help to reduce dosing of levodopa but also of dopamine agonists during long term treatment.

ExcerptRelevanceReference
" No evidence of tolerance to anti-MES activity after repeated dosing was observed."( Preclinical evaluation of PNU-151774E as a novel anticonvulsant.
Bonsignori, A; Cervini, MA; Fariello, RG; Maj, R; Marrari, P; McArthur, RA; Pevarello, P; Post, C; Salvati, P; Varasi, M; White, HS; Wolf, HH; Woodhead, JW, 1998
)
0.3
" Therefore, safinamide may be used in PD to reduce l-dopa dosage and also represents a valuable therapeutic drug to test disease-modifying potential."( Safinamide: from molecular targets to a new anti-Parkinson drug.
Caccia, C; Calabresi, M; Curatolo, L; Faravelli, L; Fariello, RG; Maestroni, S; Maj, R; Salvati, P, 2006
)
2.16
"This randomized, double-blind, placebo-, comparator (selegiline 10 mg/day)-, and positive (phenelzine 30 mg/day)-controlled study investigated the pressor response to oral tyramine under fasting conditions after the administration of safinamide at therapeutic (100 mg/day) and supratherapeutic (350 mg/day) dosing regimens in healthy volunteers for the purpose of assessing the need for dietary restrictions."( The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial.
Astruc, B; Johne, A; Kovar, A; Krösser, S; Kupas, K; Marquet, A; Patat, A, 2012
)
0.92
" Safinamide will help to reduce dosing of levodopa but also of dopamine agonists during long term treatment in patients with Parkinson's disease."( Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Müller, T, 2017
)
1.64
" AUC in the dosing interval at steady state was 13,150 and 23,100 ng • h/mL for 50 and 100 mg of safinamide."( Pharmacokinetic and Safety Study of Single and Multiple Oral Doses of Safinamide in Healthy Chinese Volunteers.
Cattaneo, C; Jing, S; Leuratti, C; Vaja, V; Yuan, Y, 2023
)
1.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amino acid amideAn amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency23.48500.00308.794948.0869AID1347053
EWS/FLI fusion proteinHomo sapiens (human)Potency13.19670.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency23.48500.00308.794948.0869AID1347053
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CholinesteraseHomo sapiens (human)IC50 (µMol)0.00520.00001.559910.0000AID1556701
CholinesteraseHomo sapiens (human)Ki0.00230.00001.51739.7300AID1556701
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)0.02100.00011.753610.0000AID1383066
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)IC50 (µMol)0.10000.00040.764912.5000AID1180468; AID1180472; AID1891761; AID298106; AID747670
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)Ki0.01100.00081.09276.0000AID1192621; AID1192622
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)IC50 (µMol)387.60000.00071.979812.5000AID1180466; AID1891759; AID298105
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)Ki0.01670.00190.55334.8000AID1192621
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)63.52350.00002.37899.7700AID1180465; AID1245396; AID1368627; AID1383065; AID1397341; AID1556700; AID1586573; AID1602879; AID1701087; AID1706696; AID1754860; AID1820836; AID1917381
Amine oxidase [flavin-containing] AHomo sapiens (human)Ki365.00000.00192.379710.0000AID1797830; AID302408
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)0.02580.00020.552110.0000AID747670
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)6.15290.00001.89149.5700AID1057042; AID1180467; AID1180471; AID1245395; AID1278145; AID1297408; AID1368626; AID1383066; AID1383067; AID1397342; AID1421880; AID1444054; AID1458404; AID1484647; AID1514581; AID1519691; AID1530602; AID1530604; AID1532335; AID1532342; AID1556701; AID1586575; AID1602880; AID1635461; AID1701088; AID1704813; AID1705912; AID1706697; AID1751717; AID1754140; AID1754141; AID1754859; AID1761632; AID1820837; AID1826352; AID1851409; AID1907519; AID1917380; AID434137; AID747669
Amine oxidase [flavin-containing] BHomo sapiens (human)Ki0.15440.00061.777110.0000AID1192621; AID1192622; AID1556701; AID1586577; AID1797831; AID302409
Sodium channel protein type 9 subunit alphaHomo sapiens (human)IC50 (µMol)66.50000.00602.77499.0000AID480274; AID480275
ReninCallithrix jacchus (white-tufted-ear marmoset)IC50 (µMol)0.08000.08003.12676.7000AID434137
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] BHomo sapiens (human)EC50 (µMol)15.00001.20004.15007.1000AID1192632
Amine oxidase [flavin-containing] BHomo sapiens (human)Kd0.18720.00900.11930.2754AID1192631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (55)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
sodium ion transportSodium channel protein type 9 subunit alphaHomo sapiens (human)
inflammatory responseSodium channel protein type 9 subunit alphaHomo sapiens (human)
circadian rhythmSodium channel protein type 9 subunit alphaHomo sapiens (human)
response to toxic substanceSodium channel protein type 9 subunit alphaHomo sapiens (human)
post-embryonic developmentSodium channel protein type 9 subunit alphaHomo sapiens (human)
sensory perception of painSodium channel protein type 9 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 9 subunit alphaHomo sapiens (human)
behavioral response to painSodium channel protein type 9 subunit alphaHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painSodium channel protein type 9 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perceptionSodium channel protein type 9 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 9 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 9 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 9 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
plasma membraneSodium channel protein type 9 subunit alphaHomo sapiens (human)
axonSodium channel protein type 9 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 9 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (204)

Assay IDTitleYearJournalArticle
AID1754859Inhibition of human recombinant MAO-B using kynuramine as substrate incubated for 20 mins measuring increase in emission signal at 400 nm multimode plate reader assay2021Bioorganic & medicinal chemistry, 07-15, Volume: 42Synthesis and biological evaluation of 3-styrylchromone derivatives as selective monoamine oxidase B inhibitors.
AID1397341Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells using tyramine as substrate preincubated for 1 hr followed by substrate addition and measured after 30 mins by resazurin dye-based fluorescence assay2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1861409Inhibition of recombinant MAO-B (unknown origin) expressed in baculovirus infected BTI cells assessed as reduction in 4-hydroxyquinoline level using kynuramine as a substrate at 1 uM incubated for 20 mins by discontinuous fluorimetric assay relative to co2022Bioorganic & medicinal chemistry, 08-15, Volume: 68Evaluation of chromane derivatives: Promising privileged scaffolds for lead discovery within Alzheimer's disease.
AID1820844Cmax in Sprague dawley rat at 5 mg/kg, po measured upto 24 hrs
AID302410Selectivity for human recombinant MAOB over human recombinant MAOA2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs.
AID1602879Inhibition of human recombinant MAO-A expressed in insect cells using p-tyramine as substrate preincubated for 30 mins followed by substrate addition measured for 15 mins by resorufin dye-based fluorescence assay2019Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8
Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure.
AID1820851Volume of distribution at steady state in Cynomolgus monkey at 1 mg/kg, iv measured upto 24 hrs
AID1761632Inhibition of recombinant human MAOB using kynuramine as substrate measured for 30 mins by fluorescence spectrophotometric assay2021European journal of medicinal chemistry, Mar-05, Volume: 2134-Oxoquinolines and monoamine oxidase: When tautomerism matters.
AID1705934Glio-protective activity against 6-OHDA-induced cell death in mouse C8D1A astrocytes at 0.25 uM preincubated for 24 hrs followed by 6-OHDA stimulation for 24 hrs by MTT assay
AID1532338Inhibition of human MAO-A expressed in baculovirus infected BTI insect cells at 10 uM using p-tyramine as substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by fluorescence-based Amplex Red MAO assay relative to cont2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
4-tert-Pentylphenoxyalkyl derivatives - Histamine H
AID1826376Inhibition of human recombinant MAO-A expressed in supersomes assessed as inhibition of 4-hydroxyquinoline formation using kynuramine as substrate at 10 uM by spectrofluorimetric analysis
AID1826353Inhibition of human recombinant AChE by Ellman's spectrophotometric assay
AID1245396Inhibition of recombinant human MAOA using p-tyramine as substrate after 30 mins by Amplex red based spectrophotometric analysis2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors.
AID1820847Oral bioavailability in Sprague dawley rat at 5 mg/kg measured upto 24 hrs
AID302408Inhibition of human recombinant MAOA expressed in Pichia pastoris2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs.
AID1706706Neuroprotective activity against 6-OHDA-induced cell death in human SH-SY5Y cells at 10 uM preincubated for 1 hr followed by 6-OHDA stimulation for 24 hrs by 7AAD staining based flow cytometric analysis2021European journal of medicinal chemistry, Jan-01, Volume: 209Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity.
AID1278145Inhibition of recombinant human MAO-B after 20 mins using 50 uM kynuramine as substrate by fluorescence spectrophotometry2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Inhibition of monoamine oxidase by benzoxathiolone analogues.
AID1754860Inhibition of human recombinant MAO-A using pargyline as incubated for 20 mins measuring increase in emission signal at 310 nm multimode plate reader assay2021Bioorganic & medicinal chemistry, 07-15, Volume: 42Synthesis and biological evaluation of 3-styrylchromone derivatives as selective monoamine oxidase B inhibitors.
AID298107Selectivity index, ratio of IC50 for rat brain mitochondria MAOA to IC50 for rat brain mitochondria MAOB2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase.
AID480274Inhibition of tetrodotoxin-sensitive Na+ channel by patch-clamp electrophysiology2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID1820852Clearance in Cynomolgus monkey rat at 1 mg/kg, iv measured upto 24 hrs
AID747669Inhibition of recombinant human MAO-B expressed in baculovirus-infected insect cells using p-tyramine as substrate incubated for 30 mins prior to substrate addition measured for 45 mins by amplex red reagent-based microplate fluorescence reader analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
AID1704814Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI cells at 1 uM using p-tyramine as substrate by fluorometric assay relative to control
AID1705935Glio-protective activity against 6-OHDA-induced cell death in mouse C8D1A astrocytes at 0.25 uM preincubated for 24 hrs followed by 6-OHDA stimulation for 24 hrs by LDH assay
AID1706697Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition and measured over 20 mins by horse-radish peroxidase/Amplex Red coupled2021European journal of medicinal chemistry, Jan-01, Volume: 209Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity.
AID1820837Inhibition of recombinant human MAO-B expressed in Sf9 cells preincubated for 15 min followed by addition of benzylamine and measured after 60 min by Luminex assay
AID1917381Inhibition of human MAO-A2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.
AID1907519Inhibition of human recombinant MAO-B using p-tyramine as substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by fluorometric analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Overcoming undesirable hERG affinity by incorporating fluorine atoms: A case of MAO-B inhibitors derived from 1 H-pyrrolo-[3,2-c]quinolines.
AID1530602Inhibition of recombinant human MAO-B expressed in baculovirus infected insect cell microsomes using kynuramine as substrate measured after 30 mins by fluorescence based assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors.
AID1383067Inhibition of human MAO-B expressed in baculovirus infected insect cell membranes using kynuramine as substrate after 15 to 20 mins by discontinuous fluorimetric method
AID1820855Half life in Cynomolgus monkey rat at 5 mg/kg, po measured upto 24 hrs
AID1519685Reversible inhibition of human microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as 4-hydroxyquinoline formation using kynuramine as substrate incubated up to 140 mins by spectrophotometric analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
AID1761635Selectivity index, ratio of IC50 for inhibition of human MAOA to IC50 for inhibition of human MAOB2021European journal of medicinal chemistry, Mar-05, Volume: 2134-Oxoquinolines and monoamine oxidase: When tautomerism matters.
AID1701087Inhibition of recombinant human MAO-A expressed in Sf9 cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition for 60 mins by Luminex assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor.
AID1180471Inhibition of human recombinant MAO-B expressed in baculovirus-infected insect cells using p-tyraimne substrate2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency.
AID298106Inhibition of rat brain mitochondria MAOB by radioenzymatic assay2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase.
AID1532335Inhibition of human MAO-B expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by fluorescence-based Amplex Red MAO assay2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
4-tert-Pentylphenoxyalkyl derivatives - Histamine H
AID1705912Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by fluorimetric analysis
AID1891759Inhibition of Sprague-Dawley rat MAO-A2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67Discovery of 3, 6-disubstituted isobenzofuran-1(3H)-ones as novel inhibitors of monoamine oxidases.
AID1706698Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B2021European journal of medicinal chemistry, Jan-01, Volume: 209Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity.
AID1826352Inhibition of human recombinant MAO-B expressed in supersomes assessed as inhibition of 4-hydroxyquinoline formation using kynuramine as substrate by spectrofluorimetric analysis
AID1751718Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI-TN- 5B1-4 insect cells at 10 uM using kynuramine as substrate preincubated for 10 mins in presence of substrate followed by enzyme addition and measured every minute for 30 mins b2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Mapping Chromone-3-Phenylcarboxamide Pharmacophore:
AID1530604Inhibition of recombinant human MAO-B expressed in baculovirus infected insect cell microsomes using kynuramine as substrate measured after 30 mins by spectrophotometric assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors.
AID1705911Displacement of [3H]-LSD from human 5HT6 receptor expressed in HEK293 cells measured after 1 hr by microbeta plate reader method
AID1519691Inhibition of human microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho2020European journal of medicinal chemistry, Jan-01, Volume: 185Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
AID480312Anticonvulsant activity in ip dosed albino mouse assessed as protection against subcutaneous metrazole-induced seizures2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID1383068Selectivity index, ratio of IC50 for human MAO-A expressed in baculovirus infected insect cell membranes without preincubation with enzyme to IC50 for human MAO-B expressed in baculovirus infected insect cell membranes without preincubation with enzyme
AID1751717Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI-TN- 5B1-4 insect cells using kynuramine as substrate preincubated for 10 mins in presence of substrate followed by enzyme addition and measured every minute for 30 mins by spectro2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Mapping Chromone-3-Phenylcarboxamide Pharmacophore:
AID1635461Inhibition of human microsomal MAO-B expressed in recombinant baculovirus infected insect BTI-TN-5B1-4 cells assessed as reduction in H2O2 production using p-tyramine as substrate after 15 mins by fluorescence assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.
AID1192622Inhibition of human recombinant soluble MAO-B expressed in Pichia pastoris incubated for 30 mins prior to substrate addition measured after 60 mins by MAO-Glo assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1232847Anticonvulsant activity in ip dosed albino Carworth Farms No. 1 mouse by maximal electroshock seizure test2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Chimeric derivatives of functionalized amino acids and α-aminoamides: compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels.
AID1780627Inhibition of recombinant MAO-B (unknown origin) assessed as reduction in 4-hydroxyquinoline level using kynuramine as a substrate at 1 uM incubated for 20 mins by discontinuous fluorimetric assay relative to control2021ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
Ugi Reaction Synthesis of Oxindole-Lactam Hybrids as Selective Butyrylcholinesterase Inhibitors.
AID1586577Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins and measured after 45 mins by Cheng-Prusoff equation analysis2019European journal of medicinal chemistry, Jan-15, Volume: 162(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID1556701Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as decrease in H2O2 production using p-tyramine as substrate incubated for 20 mins by horse-radish peroxidase/amplex red-based fluorescence method2019European journal of medicinal chemistry, Oct-01, Volume: 179Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID1780626Inhibition of recombinant MAO-A (unknown origin) assessed as reduction in 4-hydroxyquinoline level using kynuramine as a substrate at 1 uM incubated for 20 mins by discontinuous fluorimetric assay relative to control2021ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
Ugi Reaction Synthesis of Oxindole-Lactam Hybrids as Selective Butyrylcholinesterase Inhibitors.
AID1514581Inhibition of recombinant human MAOB expressed in insect cell microsomes using kynuramine as substrate measured after 20 mins by fluorescence spectrophotometry2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework.
AID1421892Reversible inhibition of human recombinant microsomal MAOB expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production at IC80 after 60 mins2018European journal of medicinal chemistry, Oct-05, Volume: 158Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID1383065Inhibition of human MAO-A expressed in baculovirus infected insect cell membranes using kynuramine as substrate after 15 to 20 mins by discontinuous fluorimetric method
AID1704810Displacement of [3H]N-alpha-methylhistamine from recombinant human histamine H3 receptor expressed in CHO-K1 cells by microbeta scintillation analysis
AID1519690Selectivity index, ratio of IC50 for human microsomal MAO-A expressed in baculovirus infected BTN-TN-5B1-4 cells to IC50 for human microsomal MAO-B expressed in baculovirus infected BTN-TN-5B1-4 cells using kynuramine as substrate2020European journal of medicinal chemistry, Jan-01, Volume: 185Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
AID1820842Volume of distribution at steady state in Sprague dawley rat at 1 mg/kg, iv measured upto 24 hrs
AID1826354Inhibition of horse serum BChE by Ellman's spectrophotometric assay
AID1701088Inhibition of recombinant human MAO-B expressed in Sf9 cells using benzylamine as substrate preincubated for 15 mins followed by substrate addition for 60 mins by Luminex assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor.
AID1851408Inhibition of human recombinant MAO-A assessed as reduction in 4-hydroxyquinoline level using kynuramine as a substrate at 10 uM preincubated for 5 mins followed by substrate addition by spectrofluorimetric analysis
AID1180468Inhibition of rat brain MAO-B using [14C]-phenylethylamine substrate after 20 mins2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency.
AID1421881Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2018European journal of medicinal chemistry, Oct-05, Volume: 158Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID1754142Selectivity index, ratio of IC50 for human MAO-A to IC50 for human MAO-B2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 43Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID1192632Inhibition of human recombinant soluble MAO-B assessed as thermal shift after 20 mins by SYPRO orange staining-based fluorescence assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1556702Selectivity index, ratio of IC50 for human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells to IC50 for human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells2019European journal of medicinal chemistry, Oct-01, Volume: 179Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID747670Inhibition of MAO-B in mitochondria-enriched Sprague-Dawley rat liver fractions using p-tyramine as substrate incubated for 30 mins prior to substrate addition measured for 45 mins by amplex red reagent-based microplate fluorescence reader analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
AID1695579Inhibition of human recombinant MAO-B at 100 uM using tyramine as substrate preincubated with enzyme for 30 mins followed by incubation with substrate for 30 mins by Amplex Red reagent based fluorometric method relative to control2020RSC medicinal chemistry, Sep-01, Volume: 11, Issue:9
Novel 1,3,4-thiadiazole compounds as potential MAO-A inhibitors - design, synthesis, biological evaluation and molecular modelling.
AID480288Protective index, ratio of TD50 for albino mouse to anticonvulsant ED50 for albino mouse2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID1180473Selectivity index, ratio of IC50 for human brain MAO-A to IC50 for human brain MAO-B2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency.
AID1820839Cmax in Sprague dawley rat at 1 mg/kg, iv measured upto 24 hrs
AID1458406Inhibition of human recombinant microsomal MAOA expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production at 100 uM after 15 mins by amplex red-based fluorescence assay2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
AID1586573Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins and measured after 45 mins by resorufin-based fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 162(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID1820834Toxicity in MPTP-induced C57BL/6 mouse model of Parkinson's disease assessed as effect on locomotor activity by measuring rearing activity at 10 mg/kg, ip pretreated for 15 mins followed by MPTP challenge and measured after 5 days post MPTP challenge
AID1532342Reversible inhibition of human MAOB2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
4-tert-Pentylphenoxyalkyl derivatives - Histamine H
AID1057042Inhibition of human MAO-B2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
AID1458408Selectivity index, ratio of IC50 for human recombinant microsomal MAOA to IC50 for human recombinant microsomal MAOB2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
AID1556714Reversible inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as enzyme residual activity by measuring H2O2 production at 50 nM using p-tyramine as substrate at initial concentration of 10 uM for fir2019European journal of medicinal chemistry, Oct-01, Volume: 179Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID1458411Reversible inhibition of human recombinant microsomal MAOB expressed in baculovirus infected BTI-TN-5B1- 4 cells assessed as decrease in H2O2 production at 40 nM after 15 mins by amplex red-based fluorescence assay2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
AID298105Inhibition of rat brain mitochondria MAOA by radioenzymatic assay2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase.
AID1751720Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected BTI-TN- 5B1-4 insect cells to IC50 for recombinant human MAO-B expressed in baculovirus infected BTI-TN- 5B1-4 insect cells using kynuramine as substrate preinc2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Mapping Chromone-3-Phenylcarboxamide Pharmacophore:
AID1917372Permeability of compound by PAMPA-BBB assay2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.
AID1851409Inhibition of human recombinant MAO-B assessed as reduction in 4-hydroxyquinoline level using kynuramine as a substrate preincubated for 5 mins followed by substrate addition by spectrofluorimetric analysis
AID1706700Reversible inhibition of recombinant human MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells at 10 times IC50 using p-tyramine as substrate preincubated for 15 mins followed by 100 fold dilution and subsequent substrate addition and measur2021European journal of medicinal chemistry, Jan-01, Volume: 209Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity.
AID1519693Inhibition of human microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation at 10 uM using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme inhibition by2020European journal of medicinal chemistry, Jan-01, Volume: 185Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
AID1180476Ratio of safinamide IC50 to compound IC50 for recombinant human MAO-B2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency.
AID1397342Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells using benzylamine as substrate preincubated for 1 hr followed by substrate addition and measured after 30 mins by resazurin dye-based fluorescence assay2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
AID1635473Reversible inhibition of human microsomal MAO-B expressed in recombinant baculovirus infected insect BTI-TN-5B1-4 cells assessed as increase in residual enzyme activity at 40 nM after 60 mins2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.
AID1586581n-Octanol-water distribution coefficient, log D of the compound at pH 7.4 after 90 mins by UV-spectrphotometric based shake-flask method2019European journal of medicinal chemistry, Jan-15, Volume: 162(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID1820845AUC (0-t) in Sprague dawley rat at 5 mg/kg, po measured upto 24 hrs
AID1635464Inhibition of human microsomal MAO-A expressed in recombinant baculovirus infected insect BTI-TN-5B1-4 cells assessed as reduction in H2O2 production at 100 uM using p-tyramine as substrate after 15 mins by fluorescence assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.
AID1072633Reversible inhibition of human MAO-B using p-tyramine as substrate at IC80 incubated for 1 hr prior to increasing substrate concentration measured for 5 hrs by fluorescence analysis2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Alkynyl-coumarinyl ethers as MAO-B inhibitors.
AID1383066Inhibition of human MAO-B expressed in baculovirus infected insect cell membranes using kynuramine as substrate preincubated for 30 mins followed by substrate addition measured after 15 to 20 mins by discontinuous fluorimetric method
AID1820836Inhibition of recombinant human MAO-A expressed in Sf9 cells preincubated for 15 min followed by addition of p-tyramine and measured after 60 min by Luminex assay
AID1444054Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells assessed as reduction in H2O2 production using p-tyramine as substrate pretreated for 30 mins followed by substrate addition after 30 mins by Amplex red reagent based2017European journal of medicinal chemistry, Apr-21, Volume: 130Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one.
AID1192629Reversible inhibition of MAO-B in rat whole brain homogenate assessed as recovered activity at 100 times IC50 incubated for 60 mins followed by 3 washes by Amplex Red assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1701089Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor.
AID1820849AUC (0-t) in Cynomolgus monkey at 1 mg/kg, iv measured upto 24 hrs
AID747668Selectivity ratio of IC50 for MAO-B in mitochondria-enriched Sprague-Dawley rat liver fractions to IC50 for recombinant human MAO-B2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
AID1192631Binding affinity to human recombinant microsomal MAO-B by ITC2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1421880Inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production by amplex red-based fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID1820850Half life in Cynomolgus monkey at 1 mg/kg, iv measured upto 24 hrs
AID1917380Inhibition of recombinant human MAO-B2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.
AID1820840AUC (0-t) in Sprague dawley rat at 1 mg/kg, iv measured upto 24 hrs
AID1751723Time dependent inhibition of recombinant human MAO-B expressed in baculovirus infected BTI-TN- 5B1-4 insect cells assessed as increase in enzyme activity at IC80 measured after 120 mins2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Mapping Chromone-3-Phenylcarboxamide Pharmacophore:
AID1907524Reversible inhibition of human recombinant MAO-B assessed as increase in enzymatic activity using p-tyramine as substrate preincubated for 30 mins followed by substrate addition and measured every 5 mins for 5 hrs by fluorescence based assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Overcoming undesirable hERG affinity by incorporating fluorine atoms: A case of MAO-B inhibitors derived from 1 H-pyrrolo-[3,2-c]quinolines.
AID1820856Oral bioavailability in Cynomolgus monkey rat at 5 mg/kg measured upto 24 hrs
AID1368626Inhibition of recombinant human MAO-B using benzylamine as substrate preincubated for 15 mins followed by substrate addition measured after 20 mins by amplex red reagent based spectrophotometric assay2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
AID1704813Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI cells using p-tyramine as substrate by fluorometric assay
AID1917382Cytotoxicity against human SH-SY5Y cells at 1 to 80 uM by MTT assay2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.
AID1826384Reversible inhibition of human recombinant MAO-B expressed in supersomes using kynuramine as substrate at 10 nM preincubated with enzyme for 1 hr and measured over 6 hrs by spectrophotometric method
AID1297408Inhibition of human recombinant MAO-B using kynuramine as substrate incubated for 20 mins by fluorescence spectrophotometric analysis2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
An evaluation of synthetic indole derivatives as inhibitors of monoamine oxidase.
AID480281Anticonvulsant activity in ip dosed albino mouse assessed as inhibition of maximal electroshock-induced seizures2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID1704811Inhibition of Electric eel AChE using ATCI as substrate incubated for 5 mins followed by substrate addition and measured after 5 mins by spectrophotometric based Ellman's method
AID1368627Inhibition of recombinant human MAO-A using p-tyramine as substrate preincubated for 15 mins followed by substrate addition measured after 20 mins by amplex red reagent based spectrophotometric assay2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
AID1820846Half life in Sprague dawley rat at 5 mg/kg, po measured upto 24 hrs
AID1754857Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B2021Bioorganic & medicinal chemistry, 07-15, Volume: 42Synthesis and biological evaluation of 3-styrylchromone derivatives as selective monoamine oxidase B inhibitors.
AID1484647Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cell microsomes using kynuramine as substrate after 20 mins by fluorescence spectroscopy2017European journal of medicinal chemistry, Jul-28, Volume: 135The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase.
AID1192621Inhibition of human recombinant microsomal MAO-B expressed in Pichia pastoris incubated for 30 mins prior to substrate addition measured after 60 mins by MAO-Glo assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1820848Cmax in Cynomolgus monkey at 1 mg/kg, iv measured upto 24 hrs
AID1826385Reversible inhibition of human recombinant MAO-B expressed in supersomes using kynuramine as substrate at 10 nM co-incubated with enzyme and measured over 6 hrs by spectrophotometric method
AID1245399Reversible inhibition of recombinant human MAOB using benzylamine as substrate at 2 uM measured after 3 times washout of drug by Amplex red based spectrophotometric analysis2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors.
AID1820838Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in Sf9 cells to IC50 for recombinant human MAO-B expressed in Sf9 cells
AID1421898Inhibition of human recombinant microsomal MAOA expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production at 100 uM by amplex red-based fluorescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID1368628Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
AID1695578Inhibition of human recombinant MAO-B at 1 mM using tyramine as substrate preincubated with enzyme for 30 mins followed by incubation with substrate for 30 mins by Amplex Red reagent based fluorometric method relative to control2020RSC medicinal chemistry, Sep-01, Volume: 11, Issue:9
Novel 1,3,4-thiadiazole compounds as potential MAO-A inhibitors - design, synthesis, biological evaluation and molecular modelling.
AID302409Inhibition of human recombinant MAOB expressed in Pichia pastoris2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs.
AID1180465Inhibition of human brain MAO-A using [14C]-5- hydroxytryptamine creatinine disulphate substrate after 30 mins2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency.
AID1704812Inhibition of equine serum BChE using BTCI as substrate incubated for 5 mins followed by substrate addition and measured after 5 mins by spectrophotometric based Ellman's method
AID1754141Inhibition of human MAO-A2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 43Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID1602881Selectivity index, ratio of IC50 for human recombinant MAO-A expressed in insect cells to IC50 for human recombinant MAO-B expressed in insect cells2019Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8
Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure.
AID1458404Inhibition of human recombinant microsomal MAOB expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production after 15 mins by amplex red-based fluorescence assay2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
AID480275Inhibition of tetrodotoxin-sensitive Na+ channel at -50 mV membrane holding potential by patch-clamp electrophysiology2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID1192633Inhibition of human recombinant soluble MAO-B assessed as change in melting temperature at 100 uM after 20 mins by SYPRO orange staining-based fluorescence assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1180472Inhibition of rat recombinant MAO-B expressed in baculovirus-infected insect cells using p-tyraimne substrate2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency.
AID747667Reversible inhibition of human MAO-B using p-tyramine as substrate at IC80 incubated for 22 mins followed by substrate addition measured for 5 hrs by fluorescence assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
AID1907526Mixed mode inhibition of human recombinant MAO-B using p-tyramine as substrate with varying concentration preincubated for 30 mins followed by substrate addition and measured every 5 mins for 5 hrs by Lineweaver-burk plot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Overcoming undesirable hERG affinity by incorporating fluorine atoms: A case of MAO-B inhibitors derived from 1 H-pyrrolo-[3,2-c]quinolines.
AID1180467Inhibition of human brain MAO-B using [14C]-phenylethylamine substrate after 20 mins2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency.
AID1602880Inhibition of human recombinant MAO-B expressed in insect cells using p-tyramine as substrate preincubated for 30 mins followed by substrate addition measured for 15 mins by resorufin dye-based fluorescence assay2019Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8
Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure.
AID1192630Reversible inhibition of MAO-B in rat whole brain homogenate assessed as recovered activity at 100 times IC50 incubated for 60 mins followed by 6 washes by Amplex Red assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1635465Selectivity index, ratio of IC50 for human microsomal MAO-A expressed in recombinant baculovirus infected insect BTI-TN-5B1-4 cells to IC50 for human microsomal MAO-B expressed in recombinant baculovirus infected insect BTI-TN-5B1-4 cells2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.
AID1820843Clearance in Sprague dawley rat at 1 mg/kg, iv measured upto 24 hrs
AID1706696Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition and measured over 20 mins by horse-radish peroxidase/Amplex Red coupled2021European journal of medicinal chemistry, Jan-01, Volume: 209Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity.
AID1891761Inhibition of Sprague-Dawley rat MAO-B2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67Discovery of 3, 6-disubstituted isobenzofuran-1(3H)-ones as novel inhibitors of monoamine oxidases.
AID1532339Reversible inhibition of human MAO-B expressed in baculovirus infected BTI insect cells at IC80 preincubated with compound and p-tyramine for 22 mins followed by p-tyramine increase to 1 mM and measured every minute for 5 hrs by fluorescence assay2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
4-tert-Pentylphenoxyalkyl derivatives - Histamine H
AID434137Inhibition of MAOB2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models.
AID1761633Inhibition of recombinant human MAOA using kynuramine as substrate at 10 uM measured for 30 mins by fluorescence spectrophotometric assay relative to control2021European journal of medicinal chemistry, Mar-05, Volume: 2134-Oxoquinolines and monoamine oxidase: When tautomerism matters.
AID480287Toxicity in ip dosed albino mouse by rotarod test2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID1530599Inhibition of recombinant human MAO-A expressed in baculovirus infected insect cell microsomes at 10 uM using kynuramine as substrate measured after 30 mins by fluorescence based assay relative to control2019European journal of medicinal chemistry, Jan-01, Volume: 161Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors.
AID1232862Anticonvulsant activity in po dosed albino Sprague-Dawley rat by maximal electroshock seizure test2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Chimeric derivatives of functionalized amino acids and α-aminoamides: compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels.
AID1754140Inhibition of human MAO-B2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 43Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID1245395Inhibition of recombinant human MAOB using benzylamine as substrate after 30 mins by Amplex red based spectrophotometric analysis2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors.
AID1556700Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as decrease in H2O2 production using p-tyramine as substrate incubated for 20 mins by horse-radish peroxidase/amplex red-based fluorescence method2019European journal of medicinal chemistry, Oct-01, Volume: 179Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID480303Anticonvulsant activity in albino mouse assessed as protection against subcutaneous metrazole-induced seizures up to 300 mg/kg, ip after 4 hrs2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID1586582Kinetic aqueous solubility of compound at 500 uM at pH 7.4 after 90 mins by UV-vis spectrophotometric analysis2019European journal of medicinal chemistry, Jan-15, Volume: 162(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID1532334Displacement of [3H]-N-alpha-methylhistamine from human H3 receptor expressed in CHO-K1 cell membranes after 60 mins by microbeta2 scintillation counting analysis2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
4-tert-Pentylphenoxyalkyl derivatives - Histamine H
AID1180466Inhibition of rat brain MAO-A using [14C]-5- hydroxytryptamine creatinine disulphate substrate after 30 mins2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency.
AID480302Anticonvulsant activity in albino mouse assessed as protection against subcutaneous metrazole-induced seizures up to 300 mg/kg, ip after 0.5 hrs2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
AID1917378Specificity index, ratio of IC50 for inhibition of human MAO-A to IC50 for inhibition of MAO-B2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.
AID1820841Half life in Sprague dawley rat at 1 mg/kg, iv measured upto 24 hrs
AID1820854AUC (0-t) in Cynomolgus monkey rat at 5 mg/kg, po measured upto 24 hrs
AID1861408Inhibition of recombinant MAO-A (unknown origin) expressed in baculovirus infected BTI cells assessed as reduction in 4-hydroxyquinoline level using kynuramine as a substrate at 1 uM incubated for 20 mins by discontinuous fluorimetric assay relative to co2022Bioorganic & medicinal chemistry, 08-15, Volume: 68Evaluation of chromane derivatives: Promising privileged scaffolds for lead discovery within Alzheimer's disease.
AID1820853Cmax in Cynomolgus monkey rat at 5 mg/kg, po measured upto 24 hrs
AID1586575Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins and measured after 45 mins by resorufin-based fluorescence assay2019European journal of medicinal chemistry, Jan-15, Volume: 162(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID1705913Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells at 1 uM using p-tyramine as substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by fluorimetric analysis relative to control
AID1057043Inhibition of human MAO-A2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1345977Human Monoamine oxidase B (Catecholamine turnover)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class.
AID1345977Human Monoamine oxidase B (Catecholamine turnover)2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
AID1797830MAO A Activity Measurement from Article 10.1021/jm070677y: \\Structures of Human Monoamine Oxidase B Complexes with Selective Noncovalent Inhibitors: Safinamide and Coumarin Analogs.\\2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs.
AID1797831MAO B Activity Measurement from Article 10.1021/jm070677y: \\Structures of Human Monoamine Oxidase B Complexes with Selective Noncovalent Inhibitors: Safinamide and Coumarin Analogs.\\2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (193)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (4.15)18.2507
2000's16 (8.29)29.6817
2010's82 (42.49)24.3611
2020's87 (45.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.30 (24.57)
Research Supply Index5.43 (2.92)
Research Growth Index5.44 (4.65)
Search Engine Demand Index129.13 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (75.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials29 (14.57%)5.53%
Reviews41 (20.60%)6.00%
Case Studies4 (2.01%)4.05%
Observational8 (4.02%)0.25%
Other117 (58.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]